United Capital Financial Advisors LLC Makes New $1.52 Million Investment in Biogen Inc. $BIIB

United Capital Financial Advisors LLC purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the 2nd quarter, HoldingsChannel.com reports. The firm purchased 7,017 shares of the biotechnology company’s stock, valued at approximately $1,516,000.

Several other hedge funds have also added to or reduced their stakes in BIIB. BlackRock Inc. bought a new position in Biogen during the 2nd quarter worth approximately $3,453,878,000. Orbimed Advisors LLC bought a new position in Biogen during the first quarter worth $11,293,000. LSV Asset Management boosted its position in Biogen by 3.3% during the fourth quarter. LSV Asset Management now owns 316,815 shares of the biotechnology company’s stock valued at $55,756,000 after acquiring an additional 9,976 shares during the last quarter. Catalyst Funds Management Pty Ltd bought a new position in shares of Biogen in the 4th quarter worth about $2,006,000. Finally, Systematic Financial Management LP lifted its stake in shares of Biogen by 256.3% in the 4th quarter. Systematic Financial Management LP now owns 16,640 shares of the biotechnology company’s stock valued at $2,928,000 after purchasing an additional 11,970 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Stock Down 1.4%

Shares of NASDAQ BIIB opened at $218.50 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. Biogen Inc. has a 1 year low of $131.52 and a 1 year high of $222.85. The stock has a market capitalization of $32.28 billion, a P/E ratio of 38.67, a P/E/G ratio of 6.81 and a beta of 0.17. The company has a 50-day moving average price of $207.81 and a 200-day moving average price of $195.68.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The firm had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. During the same period in the previous year, the company posted $5.47 EPS. The company’s revenue for the quarter was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, equities research analysts forecast that Biogen Inc. will post 12.39 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Zacks Research upgraded Biogen from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Canaccord Genuity Group lifted their price objective on shares of Biogen from $245.00 to $248.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Oppenheimer restated an “outperform” rating and issued a $300.00 price target on shares of Biogen in a report on Wednesday, July 29th. Mizuho upped their price objective on shares of Biogen from $221.00 to $241.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings lowered Biogen from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $227.79.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.